HARP Harpoon Therapeutics, Inc.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

$5.92
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/08/2019
Outstanding shares:  32,748,556
Average volume:  278,668
Market cap:   $207,625,845
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    41358P106
ISIN:        US41358P1066
Sedol:      BJ4LDP7
Valuation   (See tab for details)
PE ratio:   -1.82
PB ratio:   2.52
PS ratio:   7.74
Return on equity:   -138.40%
Net income %:   -397.18%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy